Compare Invesco NASDAQ 100 ETF (QQQM) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Smith & Nephew plc — how do they compare? Invesco NASDAQ 100 ETF trades at $290.09, while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Smith & Nephew plc pays a 2.59% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| QQQM | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $38.70 |
52-Week Low | $228.02 | $28.73 |
Market Cap | — | $12.71B |
Enterprise Value | — | $15.48B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.
The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
